These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7552510)

  • 41. Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation.
    Reichelderfer PS; Coombs RW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S19-24. PubMed ID: 7552509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cartesian coordinate analysis of viral burden and CD4+ cell count in HIV disease: implications for clinical trial design and analysis.
    Reichelderfer PS; Coombs RW
    Antiviral Res; 1996 Jan; 29(1):83-6. PubMed ID: 8721553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination antiretroviral therapy for HIV infection.
    Fischl MA
    Hosp Pract (Off Ed); 1994 Jan; 29(1):43-8. PubMed ID: 8288688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Consensus statement. Scientific Advisory Committee on Surrogate Markers of HIV.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S114-6. PubMed ID: 7552508
    [No Abstract]   [Full Text] [Related]  

  • 45. RT-PCR for Amplification of Specific Fragments of HIV-1 Genome.
    de Béthune MP; Hertogs K
    Methods Mol Med; 2000; 24():269-82. PubMed ID: 21331915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surrogate markers in HIV disease.
    Peto T
    J Antimicrob Chemother; 1996 May; 37 Suppl B():161-70. PubMed ID: 8818838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vancouver: optimism, but at a cost.
    Churchill D; Pym A; Coker R
    Int J STD AIDS; 1996 Oct; 7(6):385-7. PubMed ID: 8940665
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunological and virological surrogate markers in the evaluation of therapies for HIV infection.
    Valentine FT; Jacobson MA
    AIDS; 1990; 4 Suppl 1():S201-6. PubMed ID: 2152568
    [No Abstract]   [Full Text] [Related]  

  • 49. Laboratory markers associated with progression of HIV infection.
    Gupta V; Gupta S
    Indian J Med Microbiol; 2004; 22(1):7-15. PubMed ID: 17642679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV 2-LTR experiment design optimization.
    Cannon L; Vargas-Garcia CA; Jagarapu A; Piovoso MJ; Zurakowski R
    PLoS One; 2018; 13(11):e0206700. PubMed ID: 30408070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patients have undetectable HIV after coming off treatment.
    Hayward P
    Lancet Infect Dis; 2013 Aug; 13(8):660-1. PubMed ID: 24049782
    [No Abstract]   [Full Text] [Related]  

  • 52. HIV viral load markers in clinical practice.
    Saag MS; Holodniy M; Kuritzkes DR; O'Brien WA; Coombs R; Poscher ME; Jacobsen DM; Shaw GM; Richman DD; Volberding PA
    Nat Med; 1996 Jun; 2(6):625-9. PubMed ID: 8640545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection, prevention, and treatment of retroviral infections.
    Wells KH; Byrne BC; Poiesz BJ
    Semin Oncol; 1990 Jun; 17(3):295-320. PubMed ID: 2191437
    [No Abstract]   [Full Text] [Related]  

  • 54. 4th International Workshop on HIV Drug Resistance. Sardinia, Italy, July 6-9, 1995. Abstracts.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 3():S1-46. PubMed ID: 8605585
    [No Abstract]   [Full Text] [Related]  

  • 55. Viral load: to treat or not to treat?
    Steele FR
    Nat Med; 1995 Oct; 1(10):980. PubMed ID: 7489377
    [No Abstract]   [Full Text] [Related]  

  • 56. Health care: Bring microbial sequencing to hospitals.
    Peacock S
    Nature; 2014 May; 509(7502):557-9. PubMed ID: 24877182
    [No Abstract]   [Full Text] [Related]  

  • 57. The New York case: lessons being learned.
    Volberding PA
    Ann Intern Med; 2005 May; 142(10):866-8. PubMed ID: 15845950
    [No Abstract]   [Full Text] [Related]  

  • 58. Markers, cofactors and staging systems in the study of HIV disease progression: a review.
    Portela MC; Simpson KN
    Mem Inst Oswaldo Cruz; 1997; 92(4):437-57. PubMed ID: 9361736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [HIV-1 resistance and the clinical laboratory].
    Córdoba J; Esteban RJ; Garijo R; Molina JM; Gobernado M
    Rev Esp Quimioter; 1999; 12(4):310-316. PubMed ID: 10878522
    [No Abstract]   [Full Text] [Related]  

  • 60. Current Research on HIV Drug Resistance-A Topical Collection with "
    Ji H
    Pathogens; 2022 Aug; 11(9):. PubMed ID: 36145398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.